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Huntington’s disease and several other neurological diseases are
caused by expanded polyglutamine [poly(Gln)] tracts in different
proteins. Mechanisms for expanded (>36 Gln residues) poly(Gln)
toxicity include the formation of aggregates that recruit and seques-
ter essential cellular proteins [Preisinger, E., Jordan, B. M., Kazantsev,
A. & Housman, D. (1999) Phil. Trans. R. Soc. London B 354, 1029–1034;
Chen, S., Berthelier, V., Yang, W. & Wetzel, R. (2001) J. Mol. Biol. 311,
173–182] and functional alterations, such as improper interactions
with other proteins [Cummings, C. J. & Zoghbi, H. Y. (2000) Hum. Mol.
Genet. 9, 909–916]. Expansion above the ‘‘pathologic threshold’’ (36
Gln) has been proposed to induce a conformational transition in
poly(Gln) tracts, which has been suggested as a target for therapeutic
intervention. Here we show that structural analyses of soluble hun-
tingtin exon 1 fusion proteins with 16 to 46 glutamine residues reveal
extended structures with random coil characteristics and no evidence
for a global conformational change above 36 glutamines. An anti-
body (MW1) Fab fragment, which recognizes full-length huntingtin in
mouse brain sections, binds specifically to exon 1 constructs contain-
ing normal and expanded poly(Gln) tracts, with affinity and stoichi-
ometry that increase with poly(Gln) length. These data support a
‘‘linear lattice’’ model for poly(Gln), in which expanded poly(Gln)
tracts have an increased number of ligand-binding sites as compared
with normal poly(Gln). The linear lattice model provides a rationale
for pathogenicity of expanded poly(Gln) tracts and a structural frame-
work for drug design.
Experimental studies of polyglutamine [poly(Gln)] have his-torically been hampered by insolubility, and molecular mod-
eling, biophysical characterization of solubilized peptides, and
antibody-binding studies have provided conflicting results as to
its structure. Theoretical work suggested either random coil or
more ordered structures (e.g., a -hairpin) (reviewed in ref. 1).
Circular dichroism (CD) studies of normal poly(Gln) peptides
(Q9 or Q17 flanked by -helical peptides) (2) revealed random-
coil structures, as did normal and expanded poly(Gln) peptides
(K2QnK2; n  5–49) in aqueous solution after a disaggregation
procedure involving nonnative solvents (3). A recent NMR study
of normal and expanded poly(Gln) fused to glutathione S-
transferase also found random-coil structures (4). Several mono-
clonal antibodies preferentially bind expanded poly(Gln) on
Western blots (1C2, refs. 5 and 6; 1F8, refs. 7 and 8; 3B5H10¶;
and MW1–6, ref. 9) or in a biosensor-based assay (1C2, ref. 10),
and these results were interpreted to indicate that expanded
poly(Gln) adopts a pathologic conformation different from the
conformation of normal poly(Gln), and that the antibodies
specifically recognize this alternative conformation (8–10, ¶).
Here, we report the structural characterization of the N-terminal
poly(Gln)-containing exon 1 domain of the Huntington’s disease
(HD) protein, huntingtin. N-terminal fragments of huntingtin are
implicated in disease pathogenesis (11), and HD exon 1 is sufficient
to cause a rapidly progressing HD-like phenotype in transgenic
mice when it contains a large poly(Gln) tract (12). We have
expressed and purified thioredoxin (TRX) fusion proteins with HD
exon 1 containing 16, 25, 39, or 46 glutamines and have character-
ized these constructs by using a variety of biochemical and bio-
physical techniques, including antibody-binding studies.
Materials and Methods
Protein Preparation. Huntingtin exon 1 was expressed as a fusion
protein with Escherichia coli TRX. Inserts containing HD exon 1
with a C-terminal His6 tag produced by restriction enzyme diges-
tions or PCR amplification (requiring the addition of 10% dimethyl
sulfoxide or 10% glycerol) were subcloned into the NcoI and
BamHI sites of a pET-32a vector (Novagen) that was modified to
remove the N-terminal His6 tag. Constructs contained the TRX
gene, a linker segment (GSGSGERQHMDSPDLGTDDDDK),
the HD exon 1 insert, and a His6 tag (Fig. 1a). Constructs contain
CAG or CAACAG repeats (13), the stabilities of which were
verified by matrix-assisted laser desorption ionization (MALDI)
mass spectrometry of purified proteins and postinduction DNA
sequence analysis. TRX-tag is a control protein that contains the
TRX gene, linker, and His6 tag. Proteins were overexpressed in
BL21(DE3) cells (Novagen) and released by osmotic shock by using
a modification of a published method (14). Briefly, cells were spun
at 6,000  g for 10 min at 4°C, and pellets were resuspended in 15
mM TrisHCl, pH 8.0, and incubated 45 min with shaking at 4°C.
Osmotically shocked cells were spun at 15,000 g for 10 min at 4°C,
and the supernatant containing the protein of interest was incu-
bated with Ni nitrilotriacetate beads (Qiagen). Proteins were eluted
in 250 mM imidazole, purified by gel filtration FPLC (Superdex-75;
Amersham Pharmacia Biotech), and concentrated with an Amicon
stirred ultrafiltration cell (Millipore). Proteins were stable for weeks
at 4°C in 50 mM TrisHCl, pH 8.0150 mM NaCl1 mM PMSF1
mM EDTA.
Antibody Reagents. MW1 (IgG2b) (9) was purified from ascites
fluid by protein G affinity chromatography. Western blots were
probed with 1C2 ascites fluid (Chemicon), anti-His6 antibody
(Qiagen) (data not shown), or purified MW1, and detected with
horseradish peroxidase-conjugated goat anti-mouse IgG secondary
antibody. MW1 Fab was prepared by papain cleavage (15) with a
ratio of 1:3000 (papain:MW1 by weight) for 30 min at 35°C, purified
by using protein A affinity chromatography and gel filtration
chromatography (Superdex-75; Amersham Pharmacia Biotech),
and concentrated in 100 mM sodium acetate, pH 5.5150 mM
NaCl.
Analytical Ultracentrifugation. Protein concentrations were deter-
mined spectrophotometrically at 280 nm by using the following
extinction coefficients: HD-16Q, HD-25Q, HD-39Q, HD-46Q, and
TRX-tag, 13,940 M1cm1 [calculated (16) from the amino acid
sequences of HD exon 1 fusion proteins or TRX-tag]; MW1 Fab,
Abbreviations: poly(Gln), polyglutamine; HD, Huntington’s disease; TRX, thioredoxin; RU,
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76,620 M1cm1 [mean value calculated (16) from IgG2b Fab
sequences in the Protein Data Bank: PDB codes 1IBG, 1FAI, and
1CGS] and verified by comparing side-by-side dilutions of HD-25Q
or MW1 Fab in 6 M guanidineHCl and aqueous solution. Proteins
were dialyzed into 50 mM TrisHCl, pH 8.0150 mM NaCl and
analyzed using a Beckman–Coulter XL-I Ultima analytical ultra-
centrifuge with absorption optics. Sedimentation equilibrium ex-
periments were conducted at 16,000, 25,000, and 30,000 rpm at
25°C. Data files were processed and analyzed as described (17).
Sedimentation velocity experiments were performed at 36,000,
42,000, or 48,000 rpm (at 20° or 25°C), and the data were analyzed
with SVEDBERG (18). Each sample was spun at three concentrations
and the apparent sedimentation coefficients were corrected for
dilution and buffer effects to give s20,w
0 .
CD. Samples were dialyzed into 10 mM sodium phosphate, pH 7.0,
and filtered (0.2 m). In this buffer, proteins with expanded
poly(Gln) were not aggregated as assessed by gel filtration FPLC
chromatography or analytical ultracentrifugation. CD data were
collected from samples (6–14M) at 25°C by using an Aviv 62A DS
spectropolarimeter (Aviv Instruments, Lakewood, NJ) (1-mm
path-length cuvette). Three wavelength scans (250 to 190 nm) were
collected for each HD exon 1 fusion protein and TRX-tag with a
1-sec averaging time per data point. Data were processed with
KALEIDAGRAPH (Abelbeck Software, Reading, PA). The CD spec-
trum of TRX-tag is very similar to that of E. coli TRX (Promega).
NMR Spectroscopy. 15N-labeled HD-46Q or TRX-tag was expressed
in minimal M9 medium prepared with 15N-labeled ammonium
chloride (Aldrich) and purified. Samples were concentrated to 100
M in 50 mM sodium phosphate, pH 7.050 mM NaCl5% D2O.
Under these conditions, HD-46Q was not aggregated as shown by
the elution of the post-NMR sample at the same time point as
freshly prepared HD-46Q in gel filtration FPLC. Shigemi tubes
were used to minimize the amount of sample required. One-
dimensional 1H and two-dimensional gradient-enhanced 1H,15N
heteronuclear single quantum coherence (HSQC) NMR spectra
were acquired at 4°C on a Varian INOVA 600-MHz spectrometer
equipped with a three-axis gradient HCN probe. A 2-sec relaxation
delay and 8,610-Hz proton spectral width were used in all experi-
ments. The one-dimensional spectra were acquired with 5,024
complex points and 2,048 transients; the solvent signal was atten-
uated by presaturation. The two-dimensional spectra were acquired
with 128 complex increments, 2,500-Hz nitrogen spectral width and
64 (TRX-tag) or 256 (HD-46Q) transients. Proton chemical shifts
were referenced relative to TSP [3-(trimethylsilyl)propionic-2,2,3,3-
d4 acid, sodium salt] by means of the residual solvent resonance at
4.9846 ppm; nitrogen chemical shifts were indirectly referenced to
the proton resonance frequency.
Biosensor Binding Studies. A BIAcore 2000 biosensor system (Phar-
macia LKB Biotechnology) was used to assay interactions between
HD exon 1 fusion proteins and MW1 Fab. Binding between a
molecule coupled to a biosensor chip (ligand) and a second
molecule injected over the chip (analyte) results in surface plasmon
resonance (SPR) changes that are read out in real time as resonance
units (RU). MW1 Fab (0.02 mgml) in 5 mM sodium acetate, pH
4.6, was immobilized by standard amine coupling chemistry on a
CM5 chip (Pharmacia LKB Biotechnology) at low (380 RU),
medium (970 RU), or high (2080 RU) density. HD exon 1 fusion
proteins or TRX-tag was injected at 100 lmin at 25°C in 50 mM
TrisHCl, pH 8.0150 mM NaCl0.005% BIAcore surfactant P20.
Each injection was preceded by an identical injection over a
mock-coupled flow-cell to subtract out nonspecific responses. HD
exon 1 fusion proteins do not bind an IgG2b isotype control
antibody (PharMingen) (data not shown). Biosensor response
curves were processed and the equilibrium binding responses (Req
values) were obtained with SCRUBBER (developed by T. Morton
and D. G. Myzska; www.cores.utah.eduinteraction). Dissociation
constants (KDs) were determined by linear regression analysis of
plots of Req versus the log of the concentration of injected protein.
For each HD exon 1 fusion protein, data for three coupling densities
were globally fit in SCIENTIST (MicroMath Scientific Software, Salt
Lake City) with monovalent, bivalent (17, 19), or trivalent analyte
(see analysis in supporting information on the PNAS web site,
www.pnas.org) models and the best-fit curve was used to derive KD1,
KD2, and KD3.
Results
Solution Structure of HD Exon 1 with Normal or Expanded Poly(Gln).
We expressed TRX fusion proteins containing HD exon 1 with 16,
25, 39, or 46 glutamines (Fig. 1a). The C-terminally tagged con-
structs reported here yield exclusively full-length products that are
purified under native conditions in milligram quantities (Fig. 1b), in
contrast to previous HD exon 1 fusion proteins with N-terminal
affinity tags produced in our laboratory and by others (20), which
copurify with truncated products. Thus, we have a system for
characterizing poly(Gln) in solution within the context of a naturally
occurring sequence. In this system, HD exon 1 is soluble and
remains monomeric with up to 46 Gln at micromolar concentra-
Fig. 1. Expression and purification of HD exon 1 constructs. (a) HD exon 1 and TRX-tag constructs are represented schematically. (b) SDSPAGE analysis of purified
proteins (0.1 nmol;2.5 g of each protein) under reducing conditions.








tions as assessed by analytical ultracentrifugation (Table 1). In
contrast to TRX-tag alone, the exon 1 fusion proteins with normal
or expanded poly(Gln) are nonglobular by several measures, in-
cluding anomalous migration in size exclusion chromatography and
high frictional ratios ( ff0) in sedimentation velocity ultracentrifu-
gation (Table 1).
To determine whether the nonglobular structures of HD exon 1
contain regular secondary structures, we analyzed the fusion pro-
teins by CD. The CD spectra of HD exon 1 with different lengths
of poly(Gln) (Fig. 2a) resemble the spectra of disordered proteins.
In particular, the spectra are reminiscent of denatured collagen
(21), which has a similar high imino acid (e.g., proline) content. If
the poly(Gln) tract in HD exon 1 underwent a global folding
transition above the pathologic threshold of 36 Gln, we would
expect to observe differences between the CD spectra of HD-25Q
and HD-46Q because the poly(Gln) tract accounts for40% of the
amino acid sequence in the latter. However, the CD spectra are very
similar (Fig. 2a), with no significant differences in the wavelength
regions characteristic of regular  or  secondary structures (21).
These results are consistent with a random-coil structure for both
normal and expanded poly(Gln) tracts within HD exon 1. More-
over, the data suggest that flanking sequences in HD exon 1 (17
residues at the N terminus and 49 residues at the C terminus) do
not adopt stable or secondary structures and that their presence
does not induce a global transition in the poly(Gln) tract above the
pathologic threshold.
Because random-coil-like CD spectra have been observed for
some folded proteins (21, 22), we also performed NMR spectros-
copy to assess the structure of HD exon 1 by means of its chemical
shift dispersion. Well dispersed resonances are a hallmark of NMR
spectra of folded proteins. The one-dimensional 1H NMR spectra
of TRX-tag and HD-46Q (Fig. 2c) have identical peaks in the
spectral regions outside the extensively overlapped envelope of
resonances (Fig. 2c Insets), indicating that TRX is folded in both
proteins. The absence of additional peaks in these regions of the
HD-46Q spectrum (Fig. 2c Insets) suggests that the N-terminal
portion of HD exon 1, which contains two Phe residues (Fig. 1a)
capable of producing ring current shifts in the context of a folded
protein, does not participate in stable tertiary structure. Further-
more, in the one-dimensional spectrum (Fig. 2c) and in the 1H,15N-
HSQC spectrum (data not shown) of HD-46Q, we see little
dispersion of amide proton chemical shifts. The majority of back-
bone amide proton resonances not due to TRX-tag fall in the region
characteristic of unfolded proteins (7.7–8.7 ppm). Terminal amide
proton resonances of Gln side chains are also narrowly dispersed
about their random-coil chemical shifts (6.9 and 7.6 ppm) (23).
These regions of the spectra do not provide insight into the
structure of the proline residues of HD exon 1, which lack amide
protons and may form polyproline II helices. Such helices are
inherently flexible and have been considered a subset of random
coil, being common in unfolded proteins, even those that are not
Pro-rich (21). The data also do not exclude the possible presence of
transiently folded species, in which chemical shift perturbations
would be diminished by conformational averaging. Our conclusion
from the NMR and CD data taken together is that HD exon 1
proteins containing normal and expanded poly(Gln) tracts are
Table 1. Masses and sedimentation coefficients of HD exon 1,





S ff0§Calculated* MS† FPLC† AUC†
HD-25Q 25.2 25.2 56.4 26.2 1.58 1.9
HD-46Q 27.9 27.9 61.0 27.2 1.66 2.0
TRX-tag 14.8 14.8 19.8 15.2 1.56 1.4




*Calculated mass for protein expressed in bacteria, assuming cleavage of
N-terminal Met.
†Masses determined by mass spectrometry (MS) or sedimentation velocity ana-
lytical ultracentrifugation (AUC), or estimated from gel filtration chromatogra-
phy (FPLC). Although fusion proteins with normal or expanded poly(Gln) mi-
grate in gel filtration with high apparent molecular weights, they are
monomeric as shown by AUC.
‡Three concentrations each of HD-25Q, HD-46Q, or TRX-tag were analyzed by
sedimentation velocity and apparent sedimentation coefficients (s*) were ex-
trapolated to infinite dilution and adjusted to standard conditions of 20°C in
water (s20,w
0 ). A single concentration of MW1 Fab was analyzed and correction of
s* to infinite dilution was estimated with the program SEDNTERP (33).
§Ratio of the observed frictional coefficient ( f ) and that calculated for an anhy-
drous sphere of equivalent radius (f0), calculated according to the Teller method
with SEDNTERP (33).
MeanofcalculatedmassesfromIgG2bFabsequences intheProteinDataBank,
PDB codes 1IBG, 1FAI, and 1CGS.
Fig. 2. Structural characterization of HD exon 1. (a) CD spectra. Each curve represents the difference between the spectrum of an HD exon 1 fusion protein and the
spectrum of the TRX-tag control protein (i.e., the CD signal attributable to HD exon 1). (b) Western blots using 1C2 and MW1. Equimolar amounts of HD exon 1 fusion
proteins or TRX-tag were loaded and probed with a 1:2000 dilution of ascites fluid containing 1C2 (Chemicon) or 200 nM purified MW1. (c) Comparison between 1H
NMR spectra of TRX-tag and HD-46Q. Only the amide and aromatic proton region and the upfield-shifted methyl region are shown. (Insets) Expanded views.
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random-coil structures that do not adopt a stable conformation
involving extensive  or  secondary structures.
Western Blot Analysis of HD Exon 1. We also assessed the structure
of HD exon 1 by evaluating its binding to anti-poly(Gln) monoclo-
nal antibodies in Western blots. In contrast to previous results in
Western blots (6, 9, 10), we observe binding of 1C2 and MW1 to
both normal and expanded poly(Gln) (Fig. 2b). Thus, the epitope
recognized by these antibodies contains 16 or fewer Gln residues.
However, the signal is more intense in long poly(Gln) as compared
with short poly(Gln). To understand the molecular basis for this
pattern of binding and its implications for poly(Gln) structure, we
studied the interaction between HD exon 1 and the Fab fragment
derived from MW1 (MW1 Fab) by using analytical ultracentrifu-
gation and a biosensor binding assay.
Stoichiometry of MW1 Fab–HD Exon 1 Complexes. To determine the
number of antibody-binding sites in normal versus expanded
poly(Gln), we investigated the stoichiometries of complexes be-
tween the Fab of MW1 and HD exon 1 with 25 or 46 Gln residues
by sedimentation equilibrium analytical ultracentrifugation. Mix-
tures were analyzed with input molar ratios of MW1 Fab to HD
exon 1 that ranged from less than 1:1 to more than 3:1. The
weight-average buoyant molecular weight (w), which corresponds
to an average of all species in solution, was greater than that of free
Fab or free HD-25Q, but less than that of a 1:1 complex for all of
the input mixtures of MW1 Fab:HD-25Q, indicating that the
predominant complex formed was 1:1 at the concentrations used in
these experiments (1–4M). Input mixtures of MW1 Fab:HD-46Q
with greater than 1:1 stoichiometry, however, had a w value
significantly higher than that of a 1:1 complex when measured at the
Fig. 3. Biosensor analyses of HD exon 1–MW1 Fab interactions. (a) Representative sensorgrams in which MW1 Fab is coupled at a density of 2,080 RU and HD-25Q
(Left) or HD-46Q (Right) is injected at indicated concentrations. (b) Req versus the concentration (logarithmic scale) of injected analyte. Multivalent interactions are
favored at low concentrations of each injected protein (low RU response region) and monovalent interactions are favored at high concentrations (high RU response
region). The greatest differentiation between expanded poly(Gln) (e.g., HD-46Q) and normal poly(Gln) (e.g., HD-16Q) occurs in the low RU response region, because
of multivalent binding of HD-46Q to MW1 Fab. (c–f ) Global fits of biosensor data for HD exon 1 fusion proteins injected over MW1 Fab coupled to the chip at low,
medium, or high density. Best-fit binding curves to the experimental data points are shown as continuous lines. Alternative models that do not adequately fit the data
are shown as dashed lines.








same concentrations as MW1 Fab:HD-25Q. This increase in w
indicates the presence of higher-order complexes. Thus, the
poly(Gln) tract in HD-46Q is a multivalent antigen that has more
than one binding site for MW1 Fab.
Binding Affinity of MW1 Fab for HD Exon 1. We next used biosensor
binding studies to determine binding affinities between HD exon 1
and MW1 Fab. Injected HD exon 1 fusion proteins with normal or
expanded poly(Gln) bind immobilized MW1 Fab (Fig. 3a), and a
plot of the equilibrium response (Req) versus concentration dem-
onstrates specific responses over a large concentration range (1010
to 105 M) (Fig. 3b). None of the response curves can be fit well to
a 1:1 (monovalent analyte) binding model, suggesting that each
poly(Gln) tract interacts with two or more MW1 Fab molecules on
the chip. This hypothesis is supported by analytical ultracentrifu-
gation results showing HD-46Q is a multivalent antigen for MW1
Fab (discussed above). Because a 1:1 model does not fit the data
even at the lowest MW1 Fab coupling density that is experimentally
feasible, we used multivalent analyte models to analyze the binding
data.
Microscopic KDs [i.e., the affinity for binding one Fab arm to one
epitope on the poly(Gln) tract] can be determined from multivalent
analyte models, as shown by our previous work involving ho-
modimeric transferrin receptor (TfR) and its ligand, HFE (17, 19).
In that system, a bivalent analyte model was developed to extract
the KD1 and KD2 affinity constants from equilibrium-based data,
which describe the binding of the first and second HFE molecules
to TfR (17). In the present analysis the bivalent analyte model fits
the HD-16Q data (Fig. 3c, solid lines) but does not adequately
describe the HD-25Q, -39Q, and -46Q data (Fig. 3 d–f, dashed
lines). However, a trivalent analyte model (see supporting infor-
mation) does fit the latter data (Fig. 3 d–f, solid lines). Thus, we
derived microscopic KD values for the sequential binding of one,
two, or three MW1 Fab molecules to a single HD exon 1 molecule.
The affinities determined (Table 2) are micromolar, and they differ
modestly as a function of poly(Gln) length (e.g., a 17-fold difference
in KD1 for HD-16Q vs. HD-46Q). This modest affinity difference is
in contrast to the100-fold differences in avidity (macroscopic KD)
at low injected protein concentrations, where multivalent binding is
favored (Fig. 3b).
Discussion
The deviation of biosensor binding data from a monovalent
analyte model (Fig. 3 c–f ) and the trends in KD values deter-
mined by using bivalent and trivalent analyte models (Table 2)
are consistent with MW1 Fab binding to a ‘‘linear lattice’’ of
poly(Gln) (Fig. 4). The linear lattice model has been described
in theoretical and experimental studies of ligand interactions
with biopolymers such as DNA (24, 25) or oligosaccharides (26).
In these systems, binding affinities increase with the length of the
lattice, because of entropic (statistical) factors (24, 26) [lower KD
values for longer poly(Gln) in Table 2]. Similarly, in the absence
of positive cooperativity, affinity for binding a second molecule
is reduced (24) (larger KD2 values relative to KD1 in Table 2). The
linear lattice model is also consistent with our other data,
including the evidence from analytical ultracentrifugation of
more than one Fab binding site in HD-46Q and the evidence
from CD and NMR that HD exon 1 with both normal and
expanded poly(Gln) is a random coil. The linear lattice model is
also supported by data in the literature showing that MW1 binds
to short peptide epitopes (9 Gln) in dot-blot assays (9). Taking
all results into account, we conclude that the pathologic thresh-
old observed in CAG-expansion diseases does not correlate with
a global transition of soluble, monomeric poly(Gln) to a folded
‘‘pathologic conformation.’’ Instead, the data support a model of
poly(Gln) as a linear lattice, in which the number of binding




HD-16Q 25.3 73.9 Not applicable
HD-25Q 14.0 78.7 29†
HD-39Q 2.2 65.2 7†
HD-46Q 1.5 37.5 5†
*KDs determined from global fits of equilibrium-based biosensor data (at low,
medium, and high ligand coupling density) to the best-fit bivalent or triva-
lent binding models (Fig. 3 c–f ).
†KD3 values are not well determined because they are sensitive to possible
tetravalent (or higher valency) interactions that are not accounted for in our
binding models, which lead to artefactually low values for KD3. Lower values of
KD3 relative to KD2 are not predicted by the linear lattice model unless there is
positive cooperativity.
Fig. 4. Linear lattice model for poly(Gln). Poly(Gln) is a linear array of n repeating units (red dots). A monovalent ligand binds the lattice by interacting with several
consecutiveunits.Bindingofafirstmonovalent ligandoccurswithanaffinity that increasesmodestlywith lattice length (e.g., 14MforHD-25Qand1.5MforHD-46Q
binding MW1 Fab, Table 2). A second ligand molecule can bind to a poly(Gln) tract that contains more than one binding site, but binds with weaker affinity than the
first ligand. A multivalent ligand can bind with high avidity to a longer poly(Gln) tract by interacting with two binding sites simultaneously (the macroscopic KD is the
product of the microscopic KD1 and KD2 values). Thus, normal and pathologic poly(Gln) can be distinguished if a ligand binds multivalently only to pathologic poly(Gln).
The existence of such a multivalent ligand in vivo at concentrations below the KD for binding normal (36) poly(Gln), but above the KD for binding expanded (36)
poly(Gln) could explain the correlation between poly(Gln) length and disease incidence.
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epitopes increases with length, which accounts for the interac-
tion of poly(Gln) with MW1, and by extension, with other
anti-poly(Gln) antibodies [e.g., MW2–5 (ref. 9), 1F8 (ref. 8),
3B5H10,¶ and 1C2 (refs. 5, 6, and 10)].
The linear lattice model provides a structural framework for
poly(Gln) in vivo because the ligand whose binding we have
characterized (MW1 Fab) is derived from an antibody that recog-
nizes full-length huntingtin or HD exon 1 in mouse brain (9). In
particular, the linear lattice model suggests a structural basis for
‘‘aberrant interaction’’ mechanisms of cytotoxicity in which soluble
expanded poly(Gln) interacts abnormally with other proteins,
leading to their functional dysregulation (27). A number of proteins
have been identified that interact with normal and expanded
poly(Gln) in N-terminal huntingtin fragments (27), and in several
cases binding is enhanced for expanded poly(Gln) tracts (28–30).
The linear lattice model provides a plausible mechanism for these
observations, in that higher-affinity binding is predicted as the
poly(Gln) tract is lengthened (Table 2). Furthermore, the model
suggests that at low (i.e.,  nM) concentrations in vivo, some
multivalent ligands (e.g., multimers or monomers with more than
one binding site) may bind significantly only to expanded poly(Gln)
(Fig. 4), thereby rationalizing the pathogenicity of expanded
poly(Gln) tracts. The linear lattice model does not preclude aggre-
gation of expanded poly(Gln), which may contribute to toxicity by
recruiting andor sequestering itself or other proteins (13). Al-
though the linear lattice model does not address the structure of
aggregated poly(Gln), it can account for the structural and ligand-
binding properties of soluble poly(Gln) species that exist as random
coils during a lag period preceding aggregation in vitro (3). Our
model predicts that during this lag period, soluble expanded
poly(Gln) binds ligands with higher affinity than does normal
poly(Gln). Thus in either aberrant interaction or recruitment
sequestration models of expanded poly(Gln) toxicity, the linear
lattice model provides a structural framework for rational drug
design.
Previous drug design efforts focused mainly on targeting the
proposed pathologic conformation of expanded poly(Gln) with
small molecules or single-chain Fv (scFv) molecules (9, 31). How-
ever, our results suggest that such molecules are unlikely to dis-
criminate sufficiently between normal and expanded poly(Gln).
For example, an scFv version of MW1 would be expected to bind
normal and expanded poly(Gln) with similar affinities (10-fold
differences in KD1 for MW1 Fab binding HD-25Q or HD-46Q in
Table 2). Use of such molecules therapeutically could lead to low
specificity and potential disruption of other proteins containing
poly(Gln) [e.g., transcription factors (13)]. An alternative approach
is suggested by our demonstration that multivalent interactions with
expanded poly(Gln) lead to high-avidity binding (Fig. 3b). The
covalent linkage of monovalent compounds with micromolar af-
finities can produce a new bivalent compound for which the binding
affinity is nanomolar (32). Thus, by covalently linking two or more
scFvs or small molecule compounds, it should be possible to obtain
therapeutic agents with high avidity and specificity for pathologic
soluble poly(Gln) tracts (Fig. 4).
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